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Abstract
AIM: To investigate feasibility, morbidity and surgical 
mortality of a docetaxel-based chemotherapy regimen 
randomly administered before or after gastrectomy 
in patients suffering from locally-advanced resectable 
gastric cancer.
METHODS: Patients suffering from locally-advanced 
(T3-4 any N M0 or any T N1-3 M0) gastric carcinoma, 
staged with endoscopic ultrasound, bone scan, comput-
ed tomography, and laparoscopy, were assigned to re-
ceive four 21 d/cycles of TCF (docetaxel 75 mg/m2 day 
1, cisplatin 75 mg/m2 day 1, and fluorouracil 300 mg/m2 
per day for days 1-14), either before (Arm A) or after 
(Arm B) gastrectomy. Operative morbidity, overall mor-
tality, and severe adverse events were compared by 
intention-to-treat analysis. 
RESULTS: From November 1999 to November 2005, 
70 patients were treated. After preoperative TCF (Arm 
A), thirty-two (94%) resections were performed, 85% 
of which were R0. Pathological response was complete 
in 4 patients (11.7%), and partial in 18 (55%). No 
surgical mortality and 28.5% morbidity rate were ob-
served, similar to those of immediate surgery arm (P  = 
0.86). Serious chemotherapy adverse events tended to 
be more frequent in arm B (23% vs  11%, P  = 0.07), 
with a single death per arm. 
CONCLUSION: Surgery following docetaxel-based 
chemotherapy was safe and with similar morbidity to 
immediate surgery in patients with locally-advanced 
resectable gastric carcinoma.
© 2010 Baishideng. All rights reserved.
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INTRODUCTION
In spite of  a declining incidence in the Western world, 
gastric cancer is still a major malignant disease in many 
populations, and the second leading cause for cancer 
mortality worldwide[1]. While localized disease, limited 
to the submucosa, can be best treated surgically, with a 
long-term survival of  70%-95%, the prognosis of  locally-
advanced tumor is poorer, due to a high unresectability 
rate at presentation, and a much higher relapse rate after 
radical surgery[2], thus demanding further studies regarding 
adjuvant and neoadjuvant treatment. Docetaxel (Taxotere®; 
Sanofi-Aventis, Paris, France) has been approved for 
treatment of  metastatic gastric cancer, when combined 
with cisplatin and infused fluorouracil (TCF regimen), 
showing superiority in survival, time to progression, and 
response rate (RR) vs cisplatin/fluorouracil (CF) in a 
randomized phase Ⅲ trial[3]. A better RR for docetaxel/
cisplatin (TC) vs epirubicin/cisplatin/protracted venous 
infusion fluorouracil (ECF) has been documented in 
a randomized phase Ⅱ trial[4]. These data suggested 
investigational use TCF in a preoperative neoadjuvant 
setting. This analysis aimed to test the hypothesis that 
preoperative chemotherapy with TCF does not influence 
negatively the results of  subsequent surgery, when 
compared to immediate surgery. Primary endpoints of  
this study were operative morbidity and mortality rates; 
secondary endpoints were surgical and pathological 
assessments of  downstaging and assessment by the surgeon 
as to whether the surgery was curative or not.
MATERIALS AND METHODS
Patient selection and treatment
Patients with histologically-proven locally-advanced resect-
able gastric carcinoma (T3-4 any N M0 or any T N1-3 M0 
as defined in the 1997 TNM classification) were screened 
for eligibility. Other inclusion criteria were: World Health 
Organization (WHO) performance status ≤ 2; age 18-75 
years; adequate blood counts (white blood cell count 
≥ 4000/mm3, platelets ≥ 100 000/mm3); normal renal 
(calculated creatinine clearance ≥ 60 mL/min) and liver 
function. Patients suffering from Siewert type Ⅰ cardia 
location adenocarcinoma (extended mostly into the lower 
esophagus) were excluded. All patients underwent chest 
X-ray, gastric endoscopic ultrasound (EUS), spiral tho-
raco-abdominal computerized tomography (CT) scan, 
bone scintigraphy and staging laparoscopy to define 
nodal status and rule out distant deposits and/or perito-
neal seeding.
The trial was approved in all centers by relevant eth-
ics committees. All patients gave written informed con-
sent for participation in the trial.
Patients were stratified by center, tumor size, tumor 
location (cardia adenocarcinoma Siewert Ⅱ and Ⅲ vs tu-
mors of  the rest of  the stomach) and nodal status (N+ vs 
N-). Patients received four 21-d/cycles of  TCF (docetaxel 
75 mg/m2, 1-h Ⅳ infusion, day 1; cisplatin 75 mg/m2 4-h 
Ⅳ infusion, day 1; and 5-fluorouracil (5-FU) 300 mg/m2 
per day continuous Ⅳ infusion, days 1 to 14), either pre-
operatively (Arm A) or postoperatively (Arm B). Just be-
fore starting chemotherapy all patients underwent place-
ment of  a totally implantable central venous port. In Arm 
A, a re-evaluation was performed after 2 cycles. If  local 
progression had occurred, then the patient immediately 
underwent surgery. Otherwise two more TCF cycles were 
administered and surgery was performed within 3-5 wk 
after day 1 of  the last cycle. In Arm B, surgery was sched-
uled to take place within 1 wk after randomization. Post-
operative TCF was to be initiated 3 to 6 wk after surgery.
Perioperative complications
Data about postoperative course and complications 
were reported on hospital cards by surgical teams. 
In addition, an epidemiology nurse was in charge of  
regularly collecting microbiology data with respect to 
nosocomial infections (surgical site, pulmonary, urinary, 
and/or intravascular catheter infections). Data on hospital 
infections were regularly submitted to the infection central 
committees on a 3-mo basis.
As conclusive assessments of  surgical procedures 
remain difficult, and there is a lack of  consensus on how 
to define complications and to stratify them by severity, 
we decided to apply a single classification, proposed by 
Dindo et al[5], which is based on the evaluation of  a co-
hort of  6336 patients and the results of  a survey. In this 
classification, the therapy used to correct a specific com-
plication is the cornerstone in ranking a complication. 
For example, life-threatening complications requiring an 
intermediate or intensive care management (IC/ICU) 
have to be differentiated from complications treated 
on the ward; as such complications are associated with 
a high mortality, stress for the patients, and substantial 
resource consumption. Therefore, registered complica-
tions in both groups were analyzed accordingly, with 
the exception of  those classified as grade Ⅰ (deviation 
from the normal postoperative course without the need 
for pharmacological treatment or surgical, endoscopic 
or radiological interventions). This grade also included 
wound infections treated at bedside.
Surgery
A careful intraoperative staging of  disease was first per-
formed, in order to rule out peritoneal seeding, ovarian 
involvement, “drop” metastasis in the pelvis, or periaortic 
gross adenopathy. Attention was directed to the liver, great-
er omentum and root of  the mesentery below the trans-
verse colon. The stomach was always inspected and gently 
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palpated to assess the location and the extent of  the tumor 
and to exclude direct invasion of  adjacent structures. 
Frozen sections of  every suspect tissue were obtained 
(e.g. preaortic, infracolic nodes); intraoperative, histology-
proven recognition of  metastatic spread was considered an 
exclusion criterion. The extent of  gastrectomy depended 
on the proximal distance of  the tumor from the cardia; 
therefore, total gastrectomy was performed in all patients 
with cardia locations and in those having antral and body 
tumors in whom a 6-cm gross proximal margin could not 
be obtained. Subtotal distal gastrectomy was performed 
in the others (almost exclusively small-size body or antral 
locations). Proximal gastric resection was never carried 
out, as total gastrectomy with 2-3 cm extent to abdominal 
esophagus was chosen for all cardia locations. 
Lymphadenectomy included excision of  all N1 and 
most N2 stations (stations 7, 8, 9 and station 11), accord-
ing to the classification of  the Japanese Research Society 
for the Study of  Gastric Cancer (JRSGC)[6,7] (Table 1). 
Hepatoduodenal ligament nodes (station 12) were also dis-
sected, limiting the lymphadenectomy to the 12a station 
(left side of  the hepatic artery), and leaving undissected 
the parts b and p of  the station (right side of  the ligament 
and just posteriorly to the portal vein, respectively). Lymph 
nodes of  the surgical specimen were routinely dissected 
by experienced pathologists, using standard techniques; 
in some cases, depending on the pathologist’s judgement, 
clearing fixatives were used prior to the dissection. Sple-
nectomy was only carried out in cases of  direct invasion of  
the spleen by the tumor, or gross appearance of  metastatic 
nodes at station 10 (splenic hilum). Caudal pancreas was 
always preserved, according to the Maruyama’s technique, 
even when splenectomy was performed, unless tumor di-
rect involvement was clinically evident. 
Surgeons were asked to document the extent of  node 
dissection and to state whether the procedure was likely to 
be curative as follows: (1) Absolutely curative: absence of  
hepatic and/or peritoneal metastasis; serosa not involved; 
no infiltration within 10 mm of  the proximal resection 
line; (2) Relatively curative: as above, but serosa involved, 
and/or cancer infiltrates within 10 mm of  the proximal 
resection line, and/or nodal involvement (N stage) equals 
D number; and (3) Non-radical: resection line involve-
ment; any residual disease after resection. 
Reconstruction technique (Roux-en-Y, Braun or 
others) was entirely left to the discretion of  the surgeon.
Pathology
Pathological response to chemotherapy was centrally 
evaluated and classified as follows: (1) Complete 
response (pCR): No residual tumor could be found after 
in toto examination of  the potential tumor site. Acellular 
mucus or acellular necrosis in the gastric wall or in 
lymph nodes was not considered as residual tumor and 
therefore was not taken into consideration for staging 
(neither for T, nor for N); (2) Partial microscopic re-
sponse: Microscopic residual tumor (persistence of  mi-
croscopic islands of  tumor cells); (3) Partial macroscopic 
response: Macroscopic residual tumor, but overt necro-
sis or calcification, or downstaging of  the tumor; and (4) 
No response: Only minor necrosis and no downstaging 
of  the tumor.
Statistical analysis
Initially a target sample size at 240 patients was set, assuming 
a 3-year event-free survival rate of  20% in arm B and 35% 
in arm A (+ 15%). Trial was prematurely stopped at 70 
randomized patients, due to insufficient accrual. Only two 
centers out of  nine showed a good accrual rate, whereas 
most participating groups were not ready to be involved 
in such a multi-disciplinary approach. Moreover, some 
patients refused to participate to this kind of  trial because 
they wanted to be operated on as soon as possible. For this 
reason, these study results are underpowered to detect any 
possibly significant differences in the experimental groups. 
Nevertheless, results were descriptively compared between 
the two arms on an intention-to-treat basis, using Mann-
Whitney U-test and Kruskal-Wallis test to compare means 
and medians, respectively. χ2 or Fisher’s exact test were used 
to compare proportions. All tests were two-sided. A P value 
less than 0.05 was assumed significant. Intention-to-treat 
principle was adopted.
RESULTS
This trial was activated in November 1999 and closed in 
November 2005 due to insufficient accrual. From De-
cember 1999 to August 2005 a total of  70 patients were 
enrolled from 9 Institutions in three countries. Eighty-five 
percent of  included patients were from two Institutions; 
from Milan (IEO-European Institute of  Oncology) and 
Geneva (University Hospitals of  Geneva). One patient 
withdrew consent, did not receive any chemotherapy, 
and was excluded from the analysis. Of  the remaining 69 
patients, 34 were randomized to Arm A (TCF followed 
by surgery) and 35 to Arm B (surgery followed by TCF). 
One patient in Arm A did not receive any chemotherapy 
because he died before starting. This patient was included 
in the analysis, in agreement with the intention-to-treat 
principle. A trial profile, conforming to the Consolidated 
Standards of  Reporting Trials (CONSORT) is shown in 
Figure 1. The two groups of  patients were similar with 
respect to various characteristics (Table 2).
Table 3 shows details about surgical procedures per-
formed and pathology reports. Thirty-two patients in 
Arm A (94%) underwent laparotomy: 29 (85%) had an 
R0 resection, and two a non-radical resection; one had 
no resection due to unsuspected peritoneal carcinomato-
sis. All 35 patients in Arm B underwent laparotomy; 32 
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D1 D2
Upper third 1-2-3-4 D1+5-6-7-8-9-10-11-110
Middle third 1-3-4-5-6 D1+2-7-8 -9 -10 -11
Lower third 3-4-5-6 D1+1-7-8-9
Table 1  Extent of lymphadenectomy D1 vs  D2 according to 
the JRSGC[5,6]
JRSGC: Japanese Research Society for the Study of Gastric Cancer.
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(91%) had an R0 resection, two a non-radical resection 
and one no resection due to peritoneal carcinomatosis. 
In Arm A, pathological response was complete in 4 pa-
tients (11.7%), and partial (macro- or microscopic) in 18 
(55%). The respective proportions of  total vs subtotal 
gastrectomies, D ≥ 2 vs D1 lymph node dissections, me-
dian number of  excised lymph nodes and of  metastatic 
nodes were very similar in the two arms of  the study, 
and all differences were not statistically significant.
Postoperative mortality and morbidity events are 
detailed in Table 4; they are stratified by severity, apply-
ing the classification proposed by Dindo et al[5]. In Arm 
A these included four septic intraabdominal complica-
tions (one anastomotic leak, two abdominal abscesses 
and one infected fluid peritoneal collection), one gastro-
jejunal anastomosis bleeding, one pneumonia requiring 
ICU admission, one pulmonary embolism, one urinary 
infection, and one fever of  unknown origin. Morbidity 
events in Arm B included three septic intraabdominal 
complications (one anastomotic leak, one abdominal ab-
scess, and one infected fluid peritoneal collection), and 
six extra abdominal infections (one infected mediastinal 
collection, three pneumonias requiring ICU admission, 
and two central venous catheter-related blood stream 
infections). Three re-operations were performed, one 
in Arm A due to anastomotic hemorrhage, and two in 
Arm B, due to infected mediastinal collection and pleural 
empyema complicating severe pneumonia, respectively. 
Overall, 9 morbidity events occurred in each arm (28.5% 
in Arm A and 25.7% in Arm B). Two postoperative 
deaths occurred, in Arm B, as a consequence of  multiple 
organ failure (MOF) complicating mediastinal infected 
fluid collection, in spite of  re-operation. All these differ-
ences were not statistically significant (P = 0.86).
A total of  189 TCF cycles were administered; 118 
in Arm A and 71 in Arm B (Table 5). In Arm A, 25 pa-
tients (74%) received all 4 cycles, two patients 3 cycles, 
and six patients 2 cycles. In Arm B, only 12 patients 
received all 4 cycles (34%), five patients 3 cycles, two 
patients 2 cycles, four patients 1 cycle and 12 patients 
received no cycle. A 64-year-old female patient who 
had received one cycle of  preoperative TCF died after 
severe worsening of  performance status and dyspnoea. 
Excluding this case, serious adverse events (SAEs) oc-
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Allocated to Arm A (n  = 34)
Underwent surgery (n  = 35)
Allocated to Arm B (n  = 35)
Received post-chemotherapy 
surgery   (n  = 32)
Analyzed (n  = 35)
Received postoperative
  Chemotherapy (n  = 23)
  Completed 4 cycles (n  = 12)
Analyzed (n  = 34)
Received preoperative 
  Chemotherapy (n  = 33) 
  Completed 4 cycles (n  = 25)
Number of patients randomized (n  = 69)
Total population considered (n  = 70)
Figure 1  Trial profile conforming to the Consolidated Standards of 
Reporting Trials (CONSORT) guidelines.
Table 2  Patient characteristics
Arm A (n  = 34) Arm B (n  = 35)
Age (yr): median (range) 57 (25-75) 59 (39-76)
Male (%) 68 71
PS 0/1/2 (%) 91/6/3 86/14/0
Tumor site (%)
   Cardia 21 20
   Fundus/body 38 40
   Antrum/pylorus 41 40
Stage (by EUS + CT scan)
   ⅠB   2   1
   Ⅱ 14 13
   Ⅲ 18 21
EUS: Endoscopic ultrasound; CT: Computerized tomography.
Table 3  Details of surgical procedures and pathology
Arm A 
(n  = 32)
Arm B 
(n  = 35)
Complete resection  R0 (%) 29 (85) 32 (91)
Non-radical resection (%)    2 (5.8)    2 (5.7)
No resection pM1 (peritoneum) (%)    1 (2.9)    1 (2.8)
pCR  n (%)      4 (11.7) NA
pPR  n (%)  18 (55) NA
Total gastrectomy 20 24
Subtotal gastrectomy 11 10
D-2 lymphadenectomy 29 31
D-3 lymphadenectomy -   2
Excised lymph nodes median (range)   20 (9-39)      26 (13-76)
Metastatic lymph nodes median (range)     1 (0-23)      5 (0-50)
pCR: Pathological complete response; pPR: Pathological partial response; 
NA: Not available.
Table 4  Postoperative morbidity and mortality, ranked 
according to Dindo et al [5]
Type of complication Arm A 
(n  = 32)
Arm B 
(n  = 35)
Anastomotic leak  1-Ⅳb 1-Ⅳb
Abdominal abscess 2-Ⅲa 1-Ⅲa
Infected peritoneal collection 1-Ⅲa 1-Ⅲa
Anastomotic bleeding 1-Ⅲb 
(re-operation)
-
Pneumonia requiring ICU 1-Ⅳa 3-Ⅳa-Ⅳa, 
Ⅴ (re-operation, death)
Pulmonary embolism 1-Ⅱ -
Urinary infection 1-Ⅱ -
Fever of unknown origin 1-Ⅱ -
Mediastinal infected collection 
+ MOF
- 1-Ⅴ (re-operation, 
death)
Central venous catheter-
related blood stream infection
- 2-Ⅱ
Totala 9 (28.5%), 1 re-
operation
9 (25.7%), 2 re-
operations, 1 death
aP = 0.86. ICU: Intensive care unit; MOF: Multiple organ failure.
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curred more frequently in Arm B. In Arm A, 13 SAEs 
in 10 patients were observed (13 SAEs out of  118 cycles 
= 11%), 7 of  them infectious (3 febrile neutropenia). In 
Arm B, 16 SAEs occurred in 14 patients (16 SAEs out 
of  71 cycles = 23%). All these differences were not sta-
tistically significant (P = 0.07 and 0.15, respectively).
A 58-year-old male patient in Arm B died suddenly 
38 d after gastrectomy from severe arrhythmia and pul-
monary infection. Table 5 details reasons for cessation 
of  therapy in the two arms of  the study.
DISCUSSION
Prognosis of  locally-advanced gastric cancer is generally 
poor in Western surgical and population-based series, with 
5-year overall survival rates of  25% or less[8], in spite of  
complete excision of  the gastric and nodal components 
of  the disease[2]. This is the consequence of  a high relapse 
rate after radical surgery, and has prompted many studies 
in the last decade, aimed at improving these results by 
means of  adjuvant and neoadjuvant treatments[9-12]. 
Both these approaches remain controversial and are 
under current investigation. A large randomized trial 
[Medical Research Council Adjuvant Gastric Infusional 
Chemotherapy (MAGIC)][13], demonstrated a survival 
benefit with the use of  perioperative chemotherapy (i.e. 
pre- and postoperatively delivered) as compared with 
surgery alone. Similarly, the FFCD 9703 trial[14] showed 
an improvement in both disease free survival (DFS) 
and overall survival (OS) with the use of  perioperative 
chemotherapy (FP regimen: 5-FU continuous infusion 
+ cisplatin) as compared to surgery. To date, no trial has 
so far investigated the effects of  the same chemotherapy 
regimen given either pre- or postoperatively. 
Although our study is underpowered to detect any 
possible significant difference in short-term postoperative 
outcome, it gives some preliminary answers to questions 
not yet available in the medical literature that could be 
interesting for future studies. The first relevant inform-
ation provided by the present study is the safety of  surgery 
following a preoperative docetaxel-based chemotherapy 
regimen. In fact, we did not register any mortality and 
we had a 28.5% morbidity rate, without any significant 
difference between pre- and postoperative administration 
of  chemotherapy. Although our patient population was 
slightly different from that of  the MAGIC and FFCD 
trials, since Type Ⅰ Siewert adenocarcinomas of  the lower 
third of  the esophagus were excluded, results of  our 
study compare favorably with those of  the MAGIC trial, 
where a 45% morbidity rate and 5% mortality rate were 
observed. In the FFCD trial, postoperative morbidity was 
21% in the surgical arm, and 28% in the perioperative 
chemotherapy arm, whereas surgical mortality was 5% for 
both groups. A possible favorable factor was that 85% 
of  patients in our series were operated on in two high-
volume institutions where D2 gastrectomy is routinely 
carried out as standard treatment of  gastric cancer. Our 
results support the conclusions that D2 gastrectomy 
can be considered a safe treatment of  gastric cancer in 
Western patients, at least when performed in experienced 
centers[15], and that gastric cancer resection should 
probably be added to the growing list of  procedures 
which are safer when performed in high-volume 
institutions[16,17]. This could explain why reports from 
single large volume institutions continue to demonstrate 
low operative mortality after D2 radical gastrectomy, while 
randomized trials show no survival benefit and severely 
increased surgical mortality after this procedure[18,19].
In addition, our data indicate that chemotherapy-
related SAEs tended to be more frequent in Arm B 
(adjuvant) than in Arm A (neoadjuvant), suggesting that 
lower patient tolerance to treatment is a key factor in 
determining higher toxicity. This could be explained by 
an increased risk of gastrointestinal toxicity after surgery, 
when patients are already deeply affected in their eating 
capacity by the gastrectomy. For instance, it was shown 
that, in a population of  23 patients followed for dietary 
intake and nutritional status after total gastrectomy, no 
patient reached recommended dietary allowances by first 
monthly follow up[20].
Our trial confirms the difficulties in administer-
ing intensive adjuvant chemotherapy in gastric cancer. 
In the MAGIC trial, 34% of  patients who completed 
preoperative chemotherapy and surgery did not start 
postoperative chemotherapy, mostly owing to early pro-
gression, patient refusal and/or surgical complication. 
In the weekly-PELF trial[21], only 14% of  experimental 
arm patients completed the scheduled adjuvant treat-
ment without time and/or dose modifications. Even 
without preoperative chemotherapy, 12 patients in this 
series did not receive any adjuvant chemotherapy. The 
most frequent reasons were patient refusal and medical 
decision. However, even when adjuvant chemotherapy 
was started, only 34% of  the patients received all the 
four cycles. In the ACT-GC Group Trial (Adjuvant Che-
motherapy Trial of  TS-1 for Gastric Cancer), evaluating 
an oral fluoropyrimidine as adjuvant agent, enrollment 
was stopped after 1 year as a consequence of  the higher 
rate of  overall survival in the S-1 treated group than in 
controls who had only surgery[22]. Nevertheless, among 
the 517 patients who received S-1, 71 refused to con-
tinue treatment because of  adverse events, and in 72 the 
872 February 21, 2010|Volume 16|Issue 7|WJG|www.wjgnet.com
Arm A 
(n  = 33)
Arm B 
(n  = 23)
Total number of cycles       118         71
Causes of treatment failure
   Progression of disease 1 0
   G4 toxicity 2 6
   Death 1 1
   Patient refusal 1 1
   Investigator’s decision 2 3
   Other 1 1
   Total 8         12
Severe adverse events (% of cycles)a        13 (11)       16 (23)
No. of patients involved (% of pts. treated)b        10 (30)       14 (60)
aP = 0.07, bP = 0.15. SAE: Severe adverse event.
Table 5  Treatment administration and SAEs
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decision of  the investigators was to terminate treatment 
because of  adverse events or complications (143/571, 
25.04%). The dose of  S-1 was reduced in 219 of  the 517 
treated patients (42.4%). 
Laparoscopy has been reported to improve clinical 
staging when compared to conventional methods, iden-
tifying unexpected peritoneal or liver metastases in 
up to 20% of  operable patients[23,24]; consequently, a 
significant proportion of  patients can avoid unnecessary 
laparotomy[25]. Although in our study staging laparoscopy 
has been confirmed as an effective tool to demonstrate 
peritoneal deposits even when missed by preoperative 
CT scan, minimal peritoneal deposits were found and 
biopsied at laparotomy in 3 patients previously judged 
peritoneal seeding-free at laparoscopy. These false-negative 
results of  laparoscopy occurred within the omentum 
and/or the lesser sac, emphasizing the limits of  staging 
laparoscopy to demonstrate a minimal peritoneal spread 
in these difficult locations. Similarly, in a recent report, the 
sensitivity for detecting peritoneal carcinomatosis was 85% 
for laparoscopy[26,27]. The possible role of  the preoperative 
PET scan in reducing the rate of  false negative results of  
staging laparoscopy is currently under investigation, with 
conflicting preliminary evidence[28,29]; it seems a priori 
highly improbable that such small-volume disease could be 
detected by this imaging technique.
Finally, our data confirm the huge difficulties in 
performing this kind of  study, which requires a high 
level of  cooperation between different disciplines. 
Principal investigators analyzed the reasons for the slow 
accrual of  patients for their neoadjuvant study with 
FAMTX[30] for operable gastric cancer, and observed that 
around half  of  the participating centers were not ready 
for such a multi-disciplinary approach, not believing 
in the potential efficacy of  the neoadjuvant treatment. 
Moreover, several patients refused to participate in this 
kind of  trial because they wanted to be operated on as 
soon as possible.
In conclusion, our study does not provide information 
on efficacy of  preoperatively-delivered TCF, due to early 
discontinuation for slow accrual. It is also underpowered 
to detect any possible significant differences in short-term 
postoperative outcome. Nevertheless, data regarding TCF 
efficacy and feasibility in the preoperative setting and TCF 
feasibility in the adjuvant setting could be interesting for 
future studies. In particular, neoadjuvant TCF achieved 
promising results with a 12% pCR rate. This evidence 
prompts further studies, since patients achieving a pCR 
tend to have a much better outcome, as underlined in 
a recent phase Ⅱ trial of  preoperative chemo-radiation 
therapy for resectable gastric cancer[31]. Surgery was safe 
after TCF preoperative chemotherapy, while toxicity 
(especially gastrointestinal) made adjuvant postoperative 
TCF more difficult to administer fully compared to the 
neoadjuvant setting. These data are consistent with the 
results of  the recent FFCD trial[14], where postoperative 
chemotherapy was completed in less than 50% of  the 
patients. This should be carefully considered when an 
intensive adjuvant chemotherapy regimen is planned.
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Background
In spite of a declining incidence in the Western world, gastric cancer is still 
a major malignant disease in many populations, and the second leading 
cause for cancer mortality worldwide. While localized disease, limited to the 
submucosa, can be best treated surgically, with a long-term survival rate of 
70%-95%, the prognosis of locally-advanced tumor is poorer, due to a high 
unresectability rate at presentation, and a much higher relapse rate after 
radical surgery. Docetaxel (Taxotere®; Sanofi-Aventis, Paris, France) has 
been approved for treatment of metastatic gastric cancer, when combined 
with cisplatin and infused fluorouracil (TCF regimen), showing superiority in 
survival, time to progression, and response rate (RR) vs cisplatin/fluorouracil 
(CF) in a randomized phase Ⅲ trial. 
Research frontiers
The above mentioned results obtained in metastatic disease suggested the 
investigational use of the TCF regimen in a preoperative neoadjuvant setting. 
The present trial aimed to test the hypothesis that preoperative chemotherapy 
with TCF does not influence negatively the results of subsequent surgery, when 
compared to immediate surgery.
Innovations and breakthroughs
This trial proved that surgery is safe after TCF preoperative chemotherapy, 
while toxicity (especially gastrointestinal) makes adjuvant postoperative TCF 
more difficult to administer fully compared to the neoadjuvant setting. Moreover, 
neoadjuvant TCF achieved promising results with a 12% pCR (pathological 
complete response) rate. 
Applications 
Obtained data regarding TCF efficacy and feasibility in the preoperative setting 
and TCF feasibility in the adjuvant setting could be interesting for future studies. 
In fact, patients achieving a pCR tend to have a much better oncology outcome. 
Finally, data here presented are consistent with the results of the recent FFCD 
trial, where postoperative chemotherapy was completed in less than 50% of 
the patients. This should be carefully considered when an intensive adjuvant 
chemotherapy regimen is planned.
Peer review
This is an interesting report of the efficacy of neoadjuvant chemotherapy for 
advanced gastric cancer. 
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